||vWF-cleaving Protease Antibody
||Thrombotic Thrombocytopenic Purpura (TTP) is characterized by the acquired or congenital deficiency of ADAMTS-13 activity. An antibody inhibitor will be present in roughly half of the cases diagnosed with idiopathic TTP.
Early diagnosis is paramount. Left untreated, TTP has a mortality rate above 90%; however, rapid diagnosis and treatment with plasma exchange improve the mortality rate to below 20%.
ADAMTS-13 Antibody is an important test in the differentiation of acquired and congenital forms of TTP.